Timber Pharmaceuticals Inc

Timber Pharmaceuticals — Investor Presentation (June 2023)

37 slides from Timber Pharmaceuticals's investor presentation, Jun 29, 2023

  1. Slide 1: Corporate Overview June 2023

    TIMBER PHARMACEUTICALS Corporate Overview June 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber's technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward-looking sta

  3. Slide 3: Timber Pharmaceuticals company description

    ofp TIMBER Timber Pharmaceuticals is a specialty pharmaceutical company devoted to transforming the lives of patients with rare, high impact dermatologic diseases by utilizing advanced translational science.

  4. Slide 4: Timber Business Strategy in Rare Dermatologic Diseases

    CEP TIMBER Timber Business Strategy in Rare Dermatologic Diseases Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway Orphan Drugs: Leverage the 505(b)(2) Pathway? * Timber can be first to market by pursuing * Bypasses Phase 1 trials by utilizing proven drugs conditions for which

  5. Slide 5: Investment Highlights

    Investment Highlights s to ing rare di: dert with a focus on rare and logic diseases, led by'a management team wilh a preven track rezord in development and commercialization * Lead product candidate TMB-001 has achieved multiple FDA Milestones Breakthrough therapy status received in May 2022; Fast

  6. Slide 6: Product/Indication Strategic and Non-Strategic Programs

    E TIMBER PHARMACEUTICALS Productlindication =p Strategic Programs ‘TMB.003 (topical Sitaxsentan) Sclerotic skin diseases Non-Strategic Programs BPX-01 (topical minocyciine, 2%) ‘Acne vulgaris BPX-04 (topical minocycline, 1%) Papulopustular rosacea *leations under consideration include Darie's Diseas

  7. Slide 7: Phase 3 Program targeting Severe Congenital Ichthyosis (CI)

    Phase 3 Program targeting M Severe Congenital Ichthyosis (Cl)

  8. Slide 8: Congenital Ichthyosis disease burden

    i" fppricrcss ahd'in some severe cases, an increased susceptibility to infection * In Lamellar ichthyosis, almost the whole body can be covered and the negative impact to “ patients’ quality of life can be severe * There is no cure for Cl. Treatment for Cl focuses on managing symptoms (i.e, emollien

  9. Slide 9: TMB-001 - Topical Isotretinoin in CI

    TMB-001 - Topical Isotretinoin in Cl Patented topical formulation that minimizes systemic absorption, thereby allowing for chronic treatment : + Isotretinoin is well known as the most effective therapy for several skin conditions, i : including ichthyosis, but it is not approved for Cl and is only a

  10. Slide 10: TMB-001 - All retinoids are not the same

    TMB-001 - All retinoids are not the same + Drug Substance Safety and Efficacy + Tretinoin and Acitretin: narrower therapeutic window than isotretinoin, issues with ethanol conversion of acitretin; prolonged (2-3 year) hepatic storage + Isotretinoin: 5 biologically active metabolites gives broader sp

  11. Slide 11: TMB-001 - Phase 2a Proof of Concept Trial in CI

    cfp TIMBER TMB-001 - Phase 2a Proof of Concept Trial in Cl 408 * Randomized, double-blind, placebo controlled, bilateral comparison (e.g., left arm vs. right arm) in ages 12 and up + 19 patients; area of treatment >150 cm”, each area <6% Body Surface Area (BSA)(treatment no more than 12% BSA) + 0.1%

  12. Slide 12: Pharmacokinetics - Phase 2a Trial

    er CEP TIMBER Pharmacokinetics-Phase 2a Trial + Small number of subjects * Very low systemic Predose 1.495 (0672) 2.480(1.795) absorption over 90-day Tor Licoesi) dati) i ane soos ppusny study period. ir ce jeans * Only representative of 6- enn 12% BSA application; pos 1365035) ise , Toe 1 020) imo

  13. Slide 13: TMB-001 - Phase 2b CONTROL study design

    TMB-001 — Phase 2b CONTROL study CONTROL years of age + Clinkal and genetic diagnosis of ARC or XLRE + 10%6-9096BSA affected by CI {22 (aut of 4) VIS! assessment areas wth a scaling cote 23 Randomization tis Primary efficacy encpoit: Proportion of VIS-50" responders at Week 12 Key secondary efficacy

  14. Slide 14: Patient press story: Lizard Skin

    cep TIMBER, “They called him ‘Lizard Skin.’ Now he’s a N.J. med student confronting the condition that haunted him.” “Growing up, he knew he was different. All he had to do was look at his skin. Other kids didn’t have large, fish-like scales running up and down their limbs. Their skin didn’t itch an

  15. Slide 15: TMB-001 CONTROL Study - Efficacy Per Protocol

    oe TMB-001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIS score versus 40% in the vehicle || grOUP (nominal p= 04) Percentage of Subject Achieving IGA Success (PP n=20) 100% of the Per Protocol Population in 0.05% dose achieve

  16. Slide 16: TMB-001 CONTROL Study - Efficacy Intent to Treat

    CEP TIMBER TMB-001 CONTROL Study - Efficacy Intent to Treat (ITT) Percentage of Subjects Achieving IGA Success (TT: n=33) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIS score versus 33% in the vehicle group (nominal p=17) 55% of the ITT Population in 0.05% dose achieved a 2

  17. Slide 17: Phase 2b CONTROL study: Lamellar Ichthyosis TGM1 patient

    ¥- CONTROL TMB-001 - Phase 2b CONTROL study eo Lamellar Ichthyosis (TGM1) 39 year old patient - 0.05% treatment arm (responder) Baseline VIIS 4 V6 EOS VIIS 2 NYSE American: TMBR

  18. Slide 18: Phase 2b CONTROL study: Lamellar Ichthyosis ALOX12B patient

    TMB-001 — Phase 2b CONTROL study Lamellar Ichthyosis (ALOX12B) 21 year old patient - 0.05% treatment arm (responder) 4 CONTROL Study Baseline- lower leg Ee - EOS V6- lower leg

  19. Slide 19: Phase 2b CONTROL study: X-Linked Ichthyosis patient

    TMB-001 — Phase 2b CONTROL study Ce eaenon X-Linked Ichthyosis 54 year old patient - 0.05% treatment arm (responder) Baseline- right foot EOS V6- right foot

  20. Slide 20: Local Skin reactions - TMB-001 0.05%

    CONTROL TMB-001 — Phase 2b CONTROL study eae Local Skin reactions - TMB-001 0.05% The four most expected skin reactions were continuously evaluated: Burning/Stinging, Erythema, Edema and Erosions While present 2 weeks into treatment, severity and frequency of both Erythema and Burning/Stinging reduc

  21. Slide 21: Patient press story: Peyton

    tP “His inability to sweat also means that Peyton is unable to play many sports or exercise for long periods of time. ‘Outdoor activities are hard for Peyton; we know he tires easily and can become overheated quickly,’ his mother said. Peyton avoids most outdoor activities and does not play sports.”

  22. Slide 22: TMB-001 - Key Lessons learned from Phase 2b

    ———— eee TMB-001 - Key Lessons learned from Phase 2b cep Teen Both VIIS-50 and IGA 22 point improvement indicate improvement with TMB-001; improvements in IS and IGA correlate well Assessing Severity No noted safety difference between adults and children Genetic mutations (flinked anc ARCI) do not i

  23. Slide 23: TMB-001 - Anticipated Regulatory Milestones to U.S. Launch

    CEP TIMBER TMB-001 — Anticipated Regulatory Milestones to U.S. Launch Phase 3 study start Enrollment end Study end Clinical data Final NDA Submi PDUFA* First Subject Last Subject Last Subject Database Lock Final 6 months Consented to randomized in Last Visit and Key document following the Study. Eff

  24. Slide 24: ASCEND Study

    ASCEND stuoy

  25. Slide 25: TMB-001 - Phase 3 ASCEND study

    TMB-001 - Phase 3 ASCEND study - N=142 subjects (110 in main study, 32 in Maximal Use Study) ASCEND ‘The Phase I Stdy is designed in thee pris 4+ Period 1 Induction @ wees): Atthe begining ofthe 3-veck Induction Pevod igi subjects wll be randomized ‘Sbjct with ARCURNL ‘atin 21 doa i (2:1 ratio eithe

  26. Slide 26: Key Efficacy Measurements

    Key Efficacy Measurements u Norabie Enipsiet Changes from "se Phase 2b Trial GRMN OST RGE ESOC Bate + FDA requirement of both scaling and fissuring pealpe sre tells some ne Ties unere +The differences in proportions of subjects with iNeaat Weskl2 bene MeO 0% >4-point improvement from baseline in Wor

  27. Slide 27: Multiple Barriers to Entry

    Multiple Barriers to Entry Patents granted and pending globally Trade secrets in formulation/manufacturing + Cytotoxic, requires containment, photolabile, prone to oxidation, temperature sensitivities, stability challenges, etc. Orphan exclusivity granted for all three strategic assets —— TMB-001 WO

  28. Slide 28: TMB-001 - Market opportunity

    CEP TIMBER TMB-001 - Market opportunity Key considerations Annual peak* U.S. sales conservatively estimated at $250 million for the Cl indication by Year 5 Targeted commercial approach + Target physicians focused at major academic centers + We believe that a small commercial footprint can achieve cl

  29. Slide 29: TMB-003 - Topical Sitaxsentan: Sclerotic Skin Diseases

    TMB-003 - Topical Sitaxsentan Sclerotic Skin Diseases

  30. Slide 30: TMB-003 Topical Sitaxsentan for Sclerotic Skin Diseases

    TMB-003 Topical Sitaxsentan for Sclerotic Skin Diseases ghly Selective ET-A inhibitor Tae Highly Selective ET-A inhibito: Role of ET-A Inhibition * Sitaxsentan is a highly selective (6,500:1) ET-A receptor Endothelin-1 is a potent and long-lasting antagonist. vasoconstrictor and profibrotic known to

  31. Slide 31: Lichen Sclerosis

    Ne — CEP TIMBER Lichen Sclerosis Rare chronic disease of vulvae and perianal areas which affects approximately 160,000 women in the U.S.* * Lichen Sclerosis affects both sexes, but is predominant in women + Prevalence 0.1-1.7% of women; diagnosed more by gynecologists than dermatologists + Bimodal p

  32. Slide 32: Scleroderma

    CEP TIMBER Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin + Two potential marke! + Moderate to Severe Localized Scleroderma which generally only affects the skin { ) + More common in children, with a prevalence of approximately 90,000 people in the US. +

  33. Slide 33: Leadership Team

    adership Team TIMBER John Koconis, MBA, Chairman and CEO. + Seasoned Pharmaceutical executive with over 25 years experience leading successful teams in global markets and having launched ‘multiple market leading products in Dermatology President &t CEO of LEO Pharma (USS), established a market leadi

  34. Slide 34: Leadership Team

    TIMBER Leadership Team Joseph Lucchese, CFO + Chief Financial Officer of Timber Pharmaceuticals + Founding member and Managing Ditector of Oncology Partners; Managing Director at Bluestone Capital Partners, headed the Private Placement desk + Portfolio Manager and Chief Financial Officer ofthe Miero

  35. Slide 35: Board of Directors

    pepe Board of Directors Edward Sitar, CPA David Cohen, MD. ted peri SEC reporting and Lubor Gaal, PhD a) Dermateogy at New York University “nse wihcarre arc adenap Soe Median wee ao sees as hf ‘expres 35 C60 st several puble We soences”Altgy ana Cota Dumais, Vee Cama of ‘compan ‘Cc Afi and Oreo nd G

  36. Slide 36: Key Takeaways

    Key Takeaways Rare, High Need Large Market Multiple Shots De-Risked Management Medical Dermatology Potential on Goal Portfolio Expertise + High unmet needs + Portfolio of orphan Breakthrough + Proven mechanisms + Deep experience in with large market indications therapy status for of action with derm

  37. Slide 37: Investor contact information

    NYSE American: TMBR aps WA B ER PHARMACEUTICALS For additional Investor Information please contact: Stephanie Prince John Koconis Chairman and CEO PCG Advisory jkoconis@timberpharma.com —_sprince@pcgadvisory.com G40) B63: 0341 worew.timberpharma.com

Timber Pharmaceuticals — Investor Presentation (June 2023) on 6ix